From 1 July, adults with severe alopecia areata in South Korea will be able to claim back the cost of baricitinib (Olumiant) through the country’s National Health Insurance (NHI) system for the first time. The decision is built on strict eligibility thresholds, mandatory outcome assessments, and a two-year coverage ceiling. It is also, in terms of timing, something of a counterpoint: the announcement arrives as the NHI faces a far more contentious question about whether to bring hereditary hair loss within the public insurance framework – a proposal that is running into serious opposition from clinicians, health economists, and patient groups, and whose fiscal implications have yet to be properly defined.
Severe alopecia areata is an autoimmune condition in which the immune system attacks hair follicles, causing substantial scalp hair loss and, in advanced cases, the disappearance of eyebrows and eyelashes. The NHI already treats it as a medical condition – unlike hereditary hair loss, which has historically sat outside the system on the basis that it carries no clinical risk to life or physical function. According to Seoul Economic Daily, the Ministry of Health and Welfare decided to extend reimbursement after reviewing clinical literature, medical textbooks, and specialist input. Until the July amendment, patients covered the full drug cost themselves.
Getting onto the scheme requires meeting two concurrent tests. On prior treatment: patients must have spent at least three months on conventional therapies such as steroids or cyclosporine without cutting their Severity of Alopecia Tool (SALT) score – a standardised measure of hair loss across the scalp, expressed as a percentage – by 30% or more, or must have stopped those treatments because of adverse effects. On severity: the SALT score must be at or above 50, or between 20 and 50 if the patient has also lost both eyebrows and eyelashes. Staying on the scheme is contingent on results. At week 36, patients must have brought their SALT score down to 20 or below to retain eligibility. Assessments continue on a six-monthly basis, and the total reimbursement window is capped at two years. Supporting documentation – treatment records and photographs – is required throughout.
The transition arrangements carry their own administrative burden worth noting. Patients who were already taking baricitinib before the amendment must demonstrate retrospectively that they satisfied the new eligibility conditions when they first started treatment. Those beyond the 36-week mark must produce their week-36 assessment results, or arrange a fresh evaluation at the point the amendment comes into force. This kind of retrospective eligibility requirement is a common source of friction in coverage transitions, and one that providers and payers should anticipate when implementing comparable specialty drug reimbursement changes. For insurance professionals, the overall framework – prior treatment gate, severity floor, results-contingent continuation, documentation requirements and a fixed endpoint – represents a coherent approach to containing long-term cost exposure in outcomes-based specialty drug reimbursement.
Were the NHI not simultaneously under pressure to extend coverage to hereditary hair loss, the baricitinib announcement would be a technical update of limited broader interest. The parallel debate changes the picture considerably. The push for hereditary hair loss coverage has a longer history than the current news cycle suggests. According to BBC reporting, it first appeared as a campaign commitment during President Lee Jae Myung’s 2022 presidential run, complete with a viral promotional video. Lee lost that election. When he returned and won, the hair loss pledge did not feature in his campaign materials. It has now come back into circulation ahead of local elections scheduled for mid-2026.
At a government briefing in December 2025, Lee made the case that hair loss treatment had shifted from a cosmetic matter to what he described as “a matter of survival,” given its effects on quality of life and employment prospects. At the same session, he raised the prospect of bringing obesity drugs within the NHI as well – framing both on the basis that younger people felt excluded from a system whose benefits were not designed with them in mind. The health minister, Jeong Eun-kyeong, acknowledged at the same meeting that hereditary hair loss currently falls outside NHI coverage because it poses no threat to life or physical health.
Don S Lee, an associate professor of political science at Korea University, offered a sceptical read of the president’s intentions to the BBC: “Personally, I doubt President Lee will carry on this issue and take further action. It’s just a very strategic gesture targeting young male voters, signalling that ‘I am also caring about you.’” The local elections context, he suggested, was significant. For those trying to assess how seriously to price implementation risk, the proposal’s electoral history is relevant data.
The NHI is not in a strong position to absorb an open-ended new liability. BBC reporting put the scheme deficit at 11.4 trillion won in 2024 – approximately US$7.7 billion by the BBC’s own conversion. Separately, government projections cited by Korea Herald indicate that the system’s reserve funds, which reached 30.2 trillion won last year, could be exhausted by 2033 as demographic pressures push spending higher. A system simultaneously running deficits and drawing down reserves is not well placed to take on benefit commitments that have not yet been scoped or costed.
Chung Jae-hoon, a preventive medicine professor at Korea University College of Medicine, put the potential annual cost of hereditary hair loss coverage anywhere between 100 billion and 700 billion won, depending on how the policy was structured and how many patients sought treatment. The width of that estimate is itself informative: a sevenfold spread reflects a policy that has not yet defined its eligible population, its covered drug list or its expected uptake. It cannot be priced meaningfully in its current form.
The financial concerns are compounded by clinical ones. Chung was direct: “Male-pattern hair loss caused by aging and genetics is not a disease that threatens life or bodily function. If hair-loss treatment is covered, people will inevitably ask why treatments for poor eyesight, wrinkles, or age spots are not.” He also noted that treatments with stronger cost-effectiveness records – among them certain adult vaccines and obesity medications – currently sit outside the NHI, raising questions about sequencing and priorities.
Kim Hyun-cheol, a professor at Yonsei University College of Medicine, put the argument in terms of opportunity cost: “There are still patients with rare diseases and severe illnesses who face enormous financial burdens because innovative treatments remain outside insurance coverage or are subject to strict reimbursement standards.”
Patient groups went further still. The Korea Alliance of Patients Organization called the proposal “a dangerous populist policy” that risks destabilising the principles underpinning the NHI. The Korean Medical Association took a similar position, arguing that available funds should be directed to serious diseases first. Scepticism is not confined to the medical community. Song Ji-hoon, a 32-year-old Seoul resident who takes hair loss medication and would stand to benefit from subsidised treatment, told the BBC the proposal feels “a bit like a vote-grabbing policy.”
The government has designated hereditary hair loss as the opening topic for “Everyone’s Debate” – a structured public consultation programme whose findings feed into the policy process but carry no binding authority. A forum is scheduled for July 4. Any resulting proposal would still need to clear the Health Insurance Policy Deliberation Committee before it could take effect.
The precedent question is also live. Critics have pointed out that approving coverage for hereditary hair loss on quality-of-life grounds would make it harder to decline comparable claims for other conditions sitting at the boundary between treatment and appearance – growth hormone therapy and obesity drugs among them. Given that obesity drugs were floated at the same December briefing and justified on the same logic, that risk is not hypothetical.
The ministry has said medical necessity and cost-effectiveness will guide whatever decision is reached. Whether those criteria are applied with the same rigour as in the baricitinib case – where clinical evidence, severity thresholds and outcome contingencies shaped every aspect of the coverage design – is the question the July forum will begin to answer.
